指南与共识支持与姑息治疗

辅助全身治疗随机临床试验中健康相关生活质量的报告建议

Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer.
指南 / 共识 · Lancet Oncol · 2026-09-29

该建议由Common-Sense Oncology与EORTC提出,针对评估辅助全身治疗的随机临床试验,推荐报告出现预设HRQOL量表恶化的患者比例及恶化持续时间,并妥善处理缺失数据与间发事件。HRQOL评估应涵盖症状、功能领域和整体HRQOL,组间比较应关注关键HRQOL结局并辅以描述性结果,且HRQOL信息应纳入主要报告并更新长期评估。

要点

  • 推荐报告辅助治疗患者中预设HRQOL量表恶化的比例及持续时间。
  • HRQOL评估需包括症状、功能领域和整体HRQOL。
  • 组间比较应关注关键HRQOL结局并辅以描述性结果。

核心结论

  • 辅助治疗试验应报告预设HRQOL恶化的患者比例和持续时间,以助临床决策。

研究设计与样本

  • 本文为Common-Sense Oncology与EORTC发布的建议文件,基于辅助全身治疗随机临床试验的HRQOL报告需求制定。

主要发现

  • 辅助治疗可导致副作用并损害HRQOL,需与复发概率降低相权衡。
  • 许多辅助治疗带来的无复发生存或总生存获益较小,副作用严重程度和持续时间对决策重要。
  • 报告预设HRQOL量表恶化的比例和持续时间可促进肿瘤医生和患者的理解。

关键数值与推荐

  • 推荐报告出现预设HRQOL量表恶化的患者比例及恶化持续时间,并妥善处理缺失数据和间发事件。
  • HRQOL评估应包括症状、功能领域和整体HRQOL。
  • 组间比较应关注由肿瘤医生和患者共同定义的关键HRQOL结局,并辅以其余HRQOL领域的描述性结果。
  • HRQOL信息应纳入辅助治疗试验的主要报告,并更新长期评估以捕捉持续性HRQOL缺陷。

临床怎么用

  • 在辅助治疗试验报告中纳入HRQOL恶化比例和持续时间,辅助临床决策。
  • 使用经过验证的HRQOL量表,并预设恶化定义。
  • 组间比较时优先报告关键HRQOL结局,并描述其他领域变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The goal of adjuvant systemic therapy after locoregional treatment of cancer is to increase the probability of cure by eradicating micro-metastases. Adjuvant treatment adds side-effects and can impair health-related quality of life (HRQOL); this must be balanced against a reduction in the probability of recurrence, which has a substantial negative effect on HRQOL. Since many adjuvant therapies lead to small gains in relapse-free or overall survival, the severity and duration of treatment-related side-effects and their impact on patient functioning and overall HRQOL are relevant to clinical decision making. To facilitate understanding by oncologists and patients, we recommend reporting in publications the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration in a relevant and validated HRQOL scale, and the duration of this deterioration during and after treatment completion, with appropriate handling of missing data and intercurrent events. HRQOL assessment should include symptoms, functioning domains, and overall HRQOL. Between-group comparisons should address key HRQOL outcomes (as defined by both oncologists and patients) supplemented by descriptive outcomes across remaining HRQOL domains. Once the proportion of patients with specific adverse changes in symptoms is identified, it is possible to determine if specific patient group(s) are at particular risk for these effects. HRQOL information should be included in the primary report of trials evaluating adjuvant therapy as it is key to informed decisions about treatment choice, and updated long-term evaluation is also important to capture any lasting deficits in HRQOL.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tannock IF, Brundage M, Booth CM, et al. Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer. Lancet Oncol. 2026. PMID: 42810369. doi:10.1016/S1470-2045(26)00333-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。